Sarah Dunsmore is a program director for the Trial Innovation Network in the NCATS Division of Clinical Innovation. The Trial Innovation Network is a collaborative initiative within NCATS’ Clinical and Translational Science Awards (CTSA) Program and is composed of three key organizational partners: the Trial Innovation Centers, the Recruitment Innovation Center and the CTSA Program hubs. Prior to joining NCATS in September 2020, Dunsmore was a program director for the National Institute of General Medical Sciences, where she managed research and training grants in the areas of sepsis, innate immunity and inflammation, and molecular pharmacology.
Dunsmore has served on several trans-National Institutes of Health (NIH) committees, including the NIH Clinical Trials Operations Workgroup, NIH Inclusion Operating Procedures Workgroup and NIH Single IRB Implementation Committee.
Dunsmore received her bachelor’s degree in molecular biology and mathematics from Vanderbilt University and her doctorate in physiology from Pennsylvania State University College of Medicine. She completed postdoctoral research training at Washington University in St. Louis and held academic positions at University College London and Brigham and Women’s Hospital before joining NIH in 2006.
Dunsmore’s scientific expertise includes lung biology, signal transduction pathways, molecular and cellular mediators of innate immunity and inflammation, and critical illness and injury. She has specific expertise in sepsis clinical trials and a strong interest in adaptive clinical trial design.